Use the hyperlinks, where available to access additional clinical trial information.
A Phase 1, Open-Label, Multicenter Study to Assess Safety, Tolerability, PK, and Efficacy of MK-1084 as Monotherapy and in Combination With Pembrolizumab in Subjects With KRASG12C Mutant Advanced Solid Tumors
Eligible participants will be allocated to one of two arms depending on the type of cancer they have. Participants with advanced solid cancers with KRASG12C mutation will receive MK-1084 daily, orally, in escalating doses. Participants with first line (previously untreated) non-small lung cancer with KRASG12C mutation will receive pembrolizumab plus MK-1084. Pembrolizumab will be administered 200mg via intravenous infusion (IV) once every 21-day cycle. MK-1084 will be administered daily, orally, in escalating doses.